Xenon Pharmaceuticals Inc
XENE44.840USD
-0.170-0.38%
收盘 12/26, 16:00（美东）报价延迟15分钟
3.46B总市值
亏损市盈率 TTM
关于 Xenon Pharmaceuticals Inc 公司
Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.
Xenon Pharmaceuticals Inc简介
公司代码XENE
公司名称Xenon Pharmaceuticals Inc
上市日期Oct 17, 2014
CEOMortimer (Ian C)
员工数量316
证券类型Ordinary Share
年结日Oct 17
公司地址3650 Gilmore Way
城市VANCOUVER
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Canada
邮编V5G 4W8
电话16044843300
网址https://www.xenon-pharma.com/
公司代码XENE
上市日期Oct 17, 2014
CEOMortimer (Ian C)
Xenon Pharmaceuticals Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Gary Patou, M.D.
Dr. Gary Patou, M.D.
Independent Director
Independent Director
28.48K
--
Ms. Dawn A. (Graham) Svoronos
Ms. Dawn A. (Graham) Svoronos
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
25.00K
--
Mr. Ian C. Mortimer, CPA
Mr. Ian C. Mortimer, CPA
President, Chief Executive Officer, Principal Operating Officer, Director
President, Chief Executive Officer, Principal Operating Officer, Director
20.30K
-55.39%
Mr. Steven R. (Steve) Gannon, CPA
Mr. Steven R. (Steve) Gannon, CPA
Independent Director
Independent Director
7.14K
-0.04%
Mr. Thomas J. (Tucker) Kelly, J.D.
Mr. Thomas J. (Tucker) Kelly, J.D.
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Christopher Kenney, M.D.
Dr. Christopher Kenney, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Darren S. Cline
Mr. Darren S. Cline
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Patrick Machado, J.D.
Mr. Patrick Machado, J.D.
Independent Director
Independent Director
--
--
Dr. Gillian M. Cannon, Ph.D.
Dr. Gillian M. Cannon, Ph.D.
Independent Director
Independent Director
--
--
Mr. Justin Gover
Mr. Justin Gover
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Gary Patou, M.D.
Dr. Gary Patou, M.D.
Independent Director
Independent Director
28.48K
--
Ms. Dawn A. (Graham) Svoronos
Ms. Dawn A. (Graham) Svoronos
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
25.00K
--
Mr. Ian C. Mortimer, CPA
Mr. Ian C. Mortimer, CPA
President, Chief Executive Officer, Principal Operating Officer, Director
President, Chief Executive Officer, Principal Operating Officer, Director
20.30K
-55.39%
Mr. Steven R. (Steve) Gannon, CPA
Mr. Steven R. (Steve) Gannon, CPA
Independent Director
Independent Director
7.14K
-0.04%
Mr. Thomas J. (Tucker) Kelly, J.D.
Mr. Thomas J. (Tucker) Kelly, J.D.
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Christopher Kenney, M.D.
Dr. Christopher Kenney, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
收入明细
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
由于公司未披露，未能获取相关数据
地区USD
名称
营收
占比
Canada
0.00
0.00%
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月16日 周日
更新时间: 11月16日 周日
持股股东
股东类型
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
8.09%
Avoro Capital Advisors LLC
6.99%
Driehaus Capital Management, LLC
5.40%
BlackRock Institutional Trust Company, N.A.
5.25%
Janus Henderson Investors
5.10%
其他
69.17%
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
8.09%
Avoro Capital Advisors LLC
6.99%
Driehaus Capital Management, LLC
5.40%
BlackRock Institutional Trust Company, N.A.
5.25%
Janus Henderson Investors
5.10%
其他
69.17%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
48.11%
Investment Advisor
33.86%
Hedge Fund
25.98%
Research Firm
1.49%
Private Equity
1.01%
Sovereign Wealth Fund
0.82%
Pension Fund
0.75%
Bank and Trust
0.40%
Individual Investor
0.11%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
446
85.67M
110.86%
-494.45K
2025Q2
418
85.39M
111.27%
+856.94K
2025Q1
434
79.94M
104.19%
-5.23M
2024Q4
434
79.81M
104.31%
-4.80M
2024Q3
425
77.49M
102.39%
-3.82M
2024Q2
431
76.92M
102.03%
-4.12M
2024Q1
421
76.68M
101.81%
-2.76M
2023Q4
404
75.13M
102.42%
+7.65M
2023Q3
386
64.60M
99.41%
-3.93M
2023Q2
377
64.25M
101.09%
-4.03M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Fidelity Management & Research Company LLC
6.40M
8.3%
+244.00K
+3.96%
Jun 30, 2025
Avoro Capital Advisors LLC
5.40M
7%
-341.67K
-5.95%
Jun 30, 2025
Driehaus Capital Management, LLC
4.34M
5.62%
-249.21K
-5.44%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.12M
5.34%
+3.47M
+534.85%
Jun 30, 2025
Janus Henderson Investors
3.58M
4.64%
+252.64K
+7.60%
Jun 30, 2025
Wellington Management Company, LLP
2.17M
2.82%
-1.61M
-42.61%
Jun 30, 2025
Braidwell LP
3.61M
4.68%
+895.15K
+33.03%
Jun 30, 2025
Capital International Investors
3.18M
4.13%
+92.82K
+3.01%
Jun 30, 2025
Commodore Capital LP
3.02M
3.92%
+700.00K
+30.11%
Jun 30, 2025
Fidelity Institutional Asset Management
2.48M
3.22%
+352.87K
+16.57%
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Neuroscience and Healthcare ETF
4.41%
ALPS Medical Breakthroughs ETF
1.35%
Goldman Sachs Future Health Care Equity ETF
1.13%
Virtus LifeSci Biotech Clinical Trials ETF
0.87%
First Trust Multi-Manager Small Cap Opportunities ETF
0.8%
JPMorgan Fundamental Data Science Small Core ETF
0.57%
JPMorgan Healthcare Leaders ETF
0.53%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.45%
ProShares Ultra Nasdaq Biotechnology
0.42%
Invesco Nasdaq Biotechnology ETF
0.32%
查看更多
iShares Neuroscience and Healthcare ETF
占比4.41%
ALPS Medical Breakthroughs ETF
占比1.35%
Goldman Sachs Future Health Care Equity ETF
占比1.13%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.87%
First Trust Multi-Manager Small Cap Opportunities ETF
占比0.8%
JPMorgan Fundamental Data Science Small Core ETF
占比0.57%
JPMorgan Healthcare Leaders ETF
占比0.53%
iShares MSCI USA Small-Cap Min Vol Factor ETF
占比0.45%
ProShares Ultra Nasdaq Biotechnology
占比0.42%
Invesco Nasdaq Biotechnology ETF
占比0.32%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
Xenon Pharmaceuticals Inc的前五大股东是谁？
Xenon Pharmaceuticals Inc 的前五大股东如下：
Fidelity Management & Research Company LLC持有股份：6.40M，占总股份比例：8.30%。
Avoro Capital Advisors LLC持有股份：5.40M，占总股份比例：7.00%。
Driehaus Capital Management, LLC持有股份：4.34M，占总股份比例：5.62%。
BlackRock Institutional Trust Company, N.A.持有股份：4.12M，占总股份比例：5.34%。
Janus Henderson Investors持有股份：3.58M，占总股份比例：4.64%。
Fidelity Management & Research Company LLC持有股份：6.40M，占总股份比例：8.30%。
Avoro Capital Advisors LLC持有股份：5.40M，占总股份比例：7.00%。
Driehaus Capital Management, LLC持有股份：4.34M，占总股份比例：5.62%。
BlackRock Institutional Trust Company, N.A.持有股份：4.12M，占总股份比例：5.34%。
Janus Henderson Investors持有股份：3.58M，占总股份比例：4.64%。
Xenon Pharmaceuticals Inc的前三大股东类型是什么？
Xenon Pharmaceuticals Inc 的前三大股东类型分别是：
Fidelity Management & Research Company LLC
Avoro Capital Advisors LLC
Driehaus Capital Management, LLC
Fidelity Management & Research Company LLC
Avoro Capital Advisors LLC
Driehaus Capital Management, LLC
有多少机构持有Xenon Pharmaceuticals Inc(XENE)的股份？
截至2025Q3，共有446家机构持有Xenon Pharmaceuticals Inc的股份，合计持有的股份价值约为85.67M，占公司总股份的110.86%。与2025Q2相比，机构持股有所增加，增幅为-0.41%。
哪个业务部门对Xenon Pharmaceuticals Inc的收入贡献最大？
在FY2025Q2，--业务部门对Xenon Pharmaceuticals Inc的收入贡献最大，创收--，占总收入的--%。
